Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > BUSINESS
BUSINESS
- Valixa Filed for Prevention of CMV Disease in Organ Transplants: Mitsubishi Tanabe
March 23, 2016
- Romosozumab Yields Positive PIII Data in Male Osteoporosis: Amgen Astellas
March 23, 2016
- Higher Remission Rates in TNF Blocker-Naïve Patients Observed in Long-Term Vedolizumab Treatment
March 23, 2016
- Santen to Form JV with China’s Kerui for Generic Eye Drugs
March 23, 2016
- Opdivo Filed for Hodgkin’s Lymphoma in Japan
March 22, 2016
- Mochida to Codevelop Ajinomoto’s Oral Constipation Drug
March 22, 2016
- Jitsubo Aims to Launch Peptide Generic Drugs Using Its Unique Technologies
March 22, 2016
- Drug Makers Terminate Lysozyme, Pronase Sale after MHLW Panel Finds Them Ineffective
March 18, 2016
- Hisamitsu, Asahi Kasei End Sales Partnership for Neoxy Tape
March 18, 2016
- Meiji Seika Pharma, RIKEN Collaborate on Skin Regeneration Research
March 17, 2016
- Takeda, Orexigen to Wind Up Sales Collaboration for Contrave
March 17, 2016
- Reversal Agent for Prazaxa Filed in Japan: Boehringer
March 17, 2016
- Denka Seiken to Develop Intradermal Flu Vaccine
March 16, 2016
- J-TEC to Venture into CRO Biz for Regenerative Medicine
March 16, 2016
- Takeda Spins Out Investigational Stress Urinary Incontinence Drug to Yamada-Led US Firm
March 16, 2016
- Ethical Drug Sales Up 7.0% in January: Crecon Report
March 15, 2016
- Lilly Seeks to Block Launch of Evista Generics Approved in February
March 15, 2016
- AbbVie Launches Japan PIII Trials for All Hep C Genotypes
March 15, 2016
- MSD Files 2 Antivirals for Hep C Treatment in Japan
March 14, 2016
- Ono Beefing Up Organization for Safe Use of Opdivo, Eyes Larger Cancer Sales Force
March 11, 2016
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…